Tumor Suppressing Viruses, Genes, and Drugs

Tumor Suppressing Viruses, Genes, and Drugs

Innovative Cancer Therapy Approaches

1st Edition - October 18, 2001

Write a review

  • Editor: Hiroshi Maruta
  • Hardcover ISBN: 9780124762497
  • eBook ISBN: 9780080549026

Purchase options

Purchase options
Available
DRM-free (PDF)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Tumor Suppressing Viruses, Genes, and Drugs profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.

Readership

Oncologists, cancer researchers, geneticists, and pharmaceutical researchers.

Table of Contents


  • Contributors

    Preface

    1 Oncolytic Viruses: Virotherapy for Cancer

    I. Introduction

    II. Attributes of Replication-Selective Viruses for Cancer Treatment

    III. Approaches to Optimizing Tumor-Selective Viral Replication

    IV. Adenoviruses

    V. Poliovirus

    VI. Vesicular Stomatitis Virus

    VII. Reovirus

    VIII. Bacteria

    IX. Vaccinia Virus

    X. Herpesvirus

    XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients

    XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042)

    XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents

    XIV. Summary

    References

    2 Reovirus Therapy of Ras-Associated Cancers

    I. Introduction

    II. Reovirus Oncolysis

    III. Concluding Remarks

    References

    3 Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical

    I. Introduction

    II. Preclinical Studies of G207

    III. G207 Clinical Trial

    IV. Conclusions

    References

    4 p53 and Its Targets

    I. Introduction

    II. Activation of p53

    III. Downstream Mediators of p53

    References

    5 Prospects for Tumor Suppressor Gene Therapy: RB as an Example

    I. Introduction

    II. Functions of RB

    III. Successes with RB Gene Therapy

    IV. Perspectives

    References

    6 CDK Inhibitors: Genes and Drugs

    I. Introduction

    II. G1 Regulation

    III. p16INK4a and the Rb Pathway

    IV. p19ARF and p53 Pathway

    V. p27 and Human Cancer

    VI. Conclusions and Future Perspectives

    References

    7 CDK Inhibitors: Small Molecular Weight Compounds

    I. Introduction

    II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer

    III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures

    IV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP

    V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem

    VI. Cyclin-Dependent Kinase Inhibitors, Cellular Effects

    VII. Cyclin-Dependent Kinase Inhibitors, Antitumor Activity

    VIII. Conclusion

    References

    8 NF1 and Other RAS-Binding Peptides

    I. RAS Molecules: Normal versus Oncogenic Mutants

    II. Super GAP?

    III. RAS-Binding Fragment of NF1

    IV. c-RAF-1

    V. PI-3 Kinase

    VI. Ral GDS

    References

    9 Cytoskeletal Tumor Suppressor Genes

    I. Introduction (Historical Background)

    II. Type I Cytoskeletal Tumor Suppressors

    III. Type II Cytoskeletal Tumor Suppressors

    References

    10 TGF- Signaling and Carcinogenesis

    I. Introduction

    II. Dual Role of TGF- in Carcinogenesis

    III. TGF- Superfamily Signaling

    IV. Perturbation of TGF- Signaling in Cancer Cells

    V. Perspectives

    References

    11 DAN Gene

    I. Introduction

    II. Cloning of DAN cDNA

    III. Transfection of DAN

    IV. Role of DAN in Neuroblastomas

    V. Structural Features of the DAN Protein

    VI. Genomic Structure of DAN

    VII. DAN Family

    References

    12 Design of Hammerhead Ribozymes and Allosterically Controllable Maxizymes for Cancer Gene Therapy

    I. Introduction

    II. Ribozyme Expression System in Cells

    III. Design of the tRNAVal-Driven Ribozyme That Is Transcribed by pol III

    IV. Design of Allosterically Controlled Maxizymes

    V. Conclusion

    References

    13 Inhibitors of Angiogenesis

    I. Introduction—Angiogenesis

    II. Angiogenesis Inhibitors

    III. Future Directions

    References

    14 Geranylgeranylated RhoB Mediates the Apoptotic and Antineoplastic Effects of Farnesyltransferase Inhibitors: New Insights into Cancer Cell Suicide

    I. Introduction

    II. Do Farnesyltransferase Inhibitors Target a Unique Aspect of Neoplastic Pathophysiology?

    III. Ras Is Not a Crucial Target of Farnesyltransferase Inhibitors

    IV. RhoB Is a Crucial Target of Farnesyltransferase Inhibitors

    V. Farnesyltransferase Inhibitors Act through a Gain of Function Mechanism Involving RhoB-GG

    VI. RhoB-GG Is Required to Mediate Apoptosis by Farnesyltransferase Inhibitors

    VII. RhoB-GG and the Antiangiogenic Properties of Farnesyltransferase Inhibitors

    VIII. Clinical Implications

    IX. Summary

    References

    15 RAS Binding Compounds

    I. Introduction

    II. Ras Cycle and Ras–Raf Signaling Pathway

    III. The Structure of Ras Proteins

    IV. Drug Target Sites of Ras

    V. Conclusions and Outlook

    References

    16 Actin-Binding Drugs: MKT-077 and Chaetoglobosin K (CK)

    I. Introduction

    II. MKT-077: F-Actin Bundler

    III. Chaetoglobosin K: F-Actin Capper

    References

    17 Tyr Kinase Inhibitors as Potential Anticancer Agents: EGF Receptor and ABL Kinases

    I. Introduction

    II. Tyr Kinase Inhibitors

    III. Chronic Myelogenous Leukemia

    IV. Epidermal Growth Factor Receptor

    V. Antagonists of the Epidermal Growth Factor Receptor Extracellular Domain

    VI. Chemical Inhibitors of the Kinase Domain of the Epidermal Growth Factor Receptor

    VII. Epidermal Growth Factor Receptor Antagonists or Inhibitors Act Synergistically to Kill Tumor Cells

    VIII. The Effects of Abl Inhibitors on Leukemia

    References

    18 Antagonists of Rho Family GTPases: Blocking PAKs, ACKs, and Rock

    I. Rho Family GTPases (Rho, Rac, and CDC42)

    II. Blocking PAKs

    III. Blocking CDC42 Pathways (ACKs and N-WASP)

    IV. Blocking Rho Pathways

    V. Rac-Specific Inhibitors?

    References

    19 Integrin Antagonists as Cancer Therapeutics

    I. Introduction

    II. Signaling Pathways Activated by Integrins

    InII. Role of Integrins in Neoplastic Transformatio

    IV. Role of Integrins in Tumor-Induced Angiogenesis

    V. Integrin Antagonists as Antiangiogenesis Agents

    VI. Conclusions and Future Perspectives

    References

    20 Functional Rescue of Mutant p53 as a Strategy to Combat Cancer

    I. Introduction

    II. Multiple Pathways of p53-Induced Apoptosis

    III. Regulation of p53 Activity

    IV. Approaches toward Reactivation of Mutant p53

    V. Implications for Tumor Therapy and Future Perspectives

    References

    Index

Product details

  • No. of pages: 425
  • Language: English
  • Copyright: © Academic Press 2001
  • Published: October 18, 2001
  • Imprint: Academic Press
  • Hardcover ISBN: 9780124762497
  • eBook ISBN: 9780080549026

About the Editor

Hiroshi Maruta

Affiliations and Expertise

Ludwig Institute for Cancer Research, Victoria, Australia

Ratings and Reviews

Write a review

There are currently no reviews for "Tumor Suppressing Viruses, Genes, and Drugs"